Company / EPS (Diluted)
IOVANCE BIOTHERAPEUTICS, INC. EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$1.89
FY2025
5-year range
-$2.49 / -$1.89
FY2021-FY2025
Trend
+24.1%
vs FY2024
Sector context
#115 of 204
Health Care
What the data says
At $-1.89, IOVANCE BIOTHERAPEUTICS, INC.'s eps (diluted) ranks #115 of 204 in the Health Care sector. EPS (Diluted) has fluctuated over the past 10 years, ranging from $-2.49 in FY2024 to $-0.48 in FY2016.
Based on SEC 10-K filings.
-1.89 in FY2025.
Improved from $-2.23 to $-1.89 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#115 of 204 in Health CareTop 56% of 204This company -$1.89 Sector average -$0.98
▼
-92.9% below sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 24.1% year-over-year.
- Ranks #115 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2016.
- Lowest eps (diluted) in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.05 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.89 | +24.1% |
| FY2024 | -$2.49 | -11.7% |
| FY2023 | -$2.23 | +10.4% |
| FY2022 | -$2.49 | -11.7% |
| FY2021 | -$2.23 | -18.6% |
| FY2020 | -$1.88 | -18.2% |
| FY2019 | -$1.59 | +14.1% |
| FY2018 | -$1.85 | -198.4% |
| FY2017 | -$0.62 | -29.2% |
| FY2016 | -$0.48 | +86.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026